HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AAD "hopeful" for sunscreen rule

This article was originally published in The Rose Sheet

Executive Summary

The American Academy of Dermatology says it "does not have any specific knowledge about a release date for the sunscreen monograph" but "is hopeful that the FDA will release the sunscreen monograph as soon as possible," noting that in September FDA indicated that it aimed to publish its long-awaited final rule by the year's end. The academy announced Dec. 3 that it is closing down its "Seal of Recognition" program for sunscreens of demonstrated excellence, confident that FDA's updated guidelines are imminent (1"The Rose Sheet" Dec. 7, 2009). "The board did [also] consider the fact that given its low participation levels, the AAD seal program was not meeting its public education goals, which [were] to encourage greater use of more protective sunscreens and increase public awareness of the dangers of excessive sun exposure," AAD President David M. Pariser told "The Rose Sheet" Dec. 4. He noted that the costs associated with the seal program exceeded the revenue it generated, so it contributed no funds to the academy's awareness activities and therefore will not be missed on that count. Through its outreach initiatives, AAD has enabled its members to conduct 1.9 million free skin cancer screenings, detecting more than 188,000 suspicious lesions, including more than 21,500 suspected melanomas

You may also be interested in...

Dermatologists Expect FDA Sunscreen Rule "Soon," End Product Seal Program

The American Academy of Dermatology says its seal of approval for products offering sun protection is no longer necessary with FDA's final sunscreen rule imminent

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts